Urogen Pharma Ltd（URGN）财务数据URGNUrogen Pharma Ltd

UroGen Pharma Ltd. (URGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Zusduri, accounting for 69.6% of total sales, equivalent to $50.43M. Another important revenue stream is Jelmyto. Understanding this composition is critical for investors evaluating how URGN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, UroGen Pharma Ltd. maintains a gross margin of 90.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.15%, while the net margin is -19.81%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively URGN converts its operational activities into shareholder value.

In the context of the broader market, URGN competes directly with industry leaders such as SEPN and ZBIO. With a market capitalization of $1.87B, it holds a leading position in the sector. When comparing efficiency, URGN's gross margin of 90.93% stands against SEPN's 100.00% and ZBIO's 100.00%. Such benchmarking helps identify whether UroGen Pharma Ltd. is trading at a premium or discount relative to its financial performance.

Urogen Pharma has shown strong revenue growth, with Q2 2026 revenue reaching $72.5 million, up 73% sequentially, and a gross margin of 90.93%. However, it still reports significant net losses, narrowing to $14.4 million in Q2 2026.